Position in IBRX
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$425,301
New position
Shares Held
55,450
first reported quarter
Ownership
0.005%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Torrey Growth & Income Advisors holds $5,840,491 across 8 Biotechnology names. IBRX ranks #5 (7.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,710 | $2,103,203 | |
| 2 | VCEL |
Vericel Corp
|
44,683 | $1,437,452 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
70,547 | $904,412 | |
| 4 | MRNA |
Moderna, Inc.
|
9,350 | $474,980 | |
| 5 | IBRX |
ImmunityBio, Inc.
This page
|
55,450 | $425,301 | |
| 6 | CADL |
Candel Therapeutics, Inc.
|
67,148 | $329,025 | |
| 7 | BCAB |
BioAtla, Inc.
|
15,687 | $126,280 | |
| 8 | SPRO |
Spero Therapeutics, Inc.
|
17,025 | $39,838 |
All Filings in IBRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $425,301 | 55,450 | Shares | Sole | 2026-04-21 | |
| No filing history on record for this holder in this stock. | ||||||